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Introduction 
Cytotoxic chemotherapeutic drugs cause cardiotoxicity or 
cardiac toxicity and affect other organs like the spleen and 
the liver. Cytotoxicity is a needed aspect of a drug targeting a 
tumor, as the cytotoxic characteristic is what kills tumor 
cells. Doxorubicin is a drug used in tumor patients that have 
been established to cause cardiotoxicity. Including 
doxorubicin, several cytotoxic drugs that cause 
cardiotoxicity1-10. The very nature of the cytotoxic drug 
administered into tumor patients is to kill cells. However, 
aspects like multi-drug resistance can result in a need to 
increase drug delivery for achieving better cytotoxicity, and 
consequentially this enhances cardiotoxicity and an array of 
cytotoxicity concerns. 
Drug formulations targeting tumors can still be toxic to 
patients. While the drug target cancer cells and kills them, it 
can also affect surrounding tissues and other healthy cells as 
well. It affects the heart health, the liver and spleen 
performance, and weight and the rest of the organs. 
Researchers have studied the effect of QTsome nanoparticle 
on chemotherapeutic drug delivery and found that the 
delivery of the QT/AM-21 showed reduced cytotoxicity11-16. 
It did not affect essential organs. Combinatorial delivery of 
the PTX and QT/AM-21 demonstrated better control of 
cytotoxic effects and hence influenced the impact of 
chemotherapeutic drug actions. The QTsome nanoparticle 
/AM-21 treatment induced better tumor regression and 
enhanced anti-cancer activity and at the cost of lesser 
toxicity17-21.  
Peptide ligand reformulations are effective for safely using 
existing chemotherapeutics. Doxorubicin DOX is used for 
treating malignant tumors and has a success rate with 
tumors like leukemia and Hodgkin’s lymphoma. The adverse 
impact of this drug is that it causes severe cardiotoxicity and 
sometimes less efficient alternatives are sought for this 
reason. In the analysis of other options and effective 
formulations, researchers have argued that PEGylated 
liposomes of DOX could be just as active and be less 
cardiotoxic. Below is a presentation of the modification of 
the liposomal DOX with active ligands. Below is the 
representation of the modified pegylated liposomal DOX 
(Figure 1)22-26.  
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Figure 1: Schematic representation of pegylated liposomal doxorubicin showing the extra- liposome medium, the lipid bilayer, and 
the intra-liposome aqueous phase.  
 
Research work on drugs and multi-drug resistance have 
identified ways to improve the sensitivity of cancer cells 
such that they can be targeted into apoptosis by 
thermophoretic drugs. More specifically, the work focused 
on Redox-triggered mitoxantrone prodrug micelles and how 
multi-drug resistance (MDR) can be handled by using a re-
sensitization system. Preferential transportation of the drug 
led to stronger anti-cancer activity and increased the 
cytotoxicity of the cancer cells27-32. This study highlighted 
how in addition to drug delivery, sensitivity increasing 
formulations are necessary to direct cytotoxicity to cancer 
cells, thus reducing the toxicity to healthy cells.  
Thus, cytotoxicity in cancer drug delivery can be enhanced 
and focused on cancer cells while at the same time, ensuring 
that vital organs are not affected. This has immense 
potential in maintaining the quality of health of the cancer 
patient as they receive their treatments for cancer33-36.  
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